Serdexmethylphenidate

Serdexmethylphenidate
Clinical data
Other names	SDX
License data	US DailyMed: Serdexmethylphenidate;
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	US: Schedule IV;
Pharmacokinetic data
Bioavailability	< 3% (absolute oral)
Metabolites	Dexmethylphenidate, ritalinic acid
Identifiers
CAS Number	1996626-29-9 ; 1996626-30-2;
PubChem CID	134823895; 134823897;
DrugBank	DB16629; DBSALT003162;
ChemSpider	81367537; 81368035;
UNII	0H8KZ470DW; FN54BT298Y;
KEGG	D11401;
ChEMBL	ChEMBL4298139;
Chemical and physical data
Formula	C25H29N3O8
Molar mass	499.520 g·mol−1
3D model (JSmol)	Interactive image; Interactive image;
	SMILES COC(=O)C(C1CCCCN1C(=O)OC[N+]2=CC=CC(=C2)C(=O)NC(CO)C(=O)[O-])C3=CC=CC=C3; ; COC(=O)[C@@H]([C@H]1CCCCN1C(=O)OC[N+]2=CC=CC(=C2)C(=O)N[C@@H](CO)C(=O)O)C3=CC=CC=C3.[Cl-];
	InChI InChI=1S/C25H29N3O8/c1-35-24(33)21(17-8-3-2-4-9-17)20-11-5-6-13-28(20)25(34)36-16-27-12-7-10-18(14-27)22(30)26-19(15-29)23(31)32/h2-4,7-10,12,14,19-21,29H,5-6,11,13,15-16H2,1H3,(H-,26,30,31,32)/t19-,20+,21+/m0/s1; Key:UBZPNQRBUOBBLN-PWRODBHTSA-N; ; InChI=1S/C25H29N3O8.ClH/c1-35-24(33)21(17-8-3-2-4-9-17)20-11-5-6-13-28(20)25(34)36-16-27-12-7-10-18(14-27)22(30)26-19(15-29)23(31)32;/h2-4,7-10,12,14,19-21,29H,5-6,11,13,15-16H2,1H3,(H-,26,30,31,32);1H/t19-,20+,21+;/m0./s1; Key:GONQEUJYYMYNMN-HWAJWLCKSA-N;
	(verify)

Serdexmethylphenidate is a prodrug of dexmethylphenidate created by the pharmaceutical company Zevra Therapeutics. The compound was first approved by the FDA as one of the active ingredients in Azstarys for the treatment of attention deficit hyperactivity disorder (ADHD) in children, adolescents, and adults in March 2021.^[2]^[3] Serdexmethylphenidate is a prodrug which has a delayed onset of action and a prolonged duration of effects compared to dexmethylphenidate, its parent compound.

^ "Schedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV". Federal Register. 24 June 2022. Retrieved 4 May 2024.
^ ^a ^b ^c "Azstarys- serdexmethylphenidate and dexmethylphenidate capsule". DailyMed. 3 November 2022. Retrieved 13 April 2023.
^ KemPharm (3 March 2021). "KemPharm Announces FDA Approval of Azstarys (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD" (Press release). KemPharm. Retrieved 17 May 2021 – via GlobeNewswire.

[1] "Schedules of Controlled Substances: Placement of Serdexmethylphenidate in Schedule IV". Federal Register. 24 June 2022. Retrieved 4 May 2024.

[Azstarys_FDA_label-2] "Azstarys- serdexmethylphenidate and dexmethylphenidate capsule". DailyMed. 3 November 2022. Retrieved 13 April 2023.

[3] KemPharm (3 March 2021). "KemPharm Announces FDA Approval of Azstarys (serdexmethylphenidate and dexmethylphenidate capsules, for oral use, CII), A New Once-Daily Treatment for ADHD" (Press release). KemPharm. Retrieved 17 May 2021 – via GlobeNewswire.

[1]

[2]

[3]